Combined Anabolic Therapy Study
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
In this research study the study investigators want to learn more about the effect of two different FDA-approved medication regimens in the treatment of postmenopausal osteoporosis.
Eligibility
Participation Requirements
Sex: Female
Minimum Age: 45
Healthy Volunteers: t
View:
• women aged 45+
• postmenopausal
• osteoporotic with high risk of fracture
Locations
United States
Massachusetts
Massachusetts General Hospital
RECRUITING
Boston
Contact Information
Primary
Aparna Patnaik, BA
apatnaik1@mgh.harvard.edu
617-726-6129
Time Frame
Start Date: 2025-02-03
Estimated Completion Date: 2027-07-01
Participants
Target number of participants: 50
Treatments
Active_comparator: Romosozumab
romosozumab
Active_comparator: Romosozumab and Teriparatide
romosozumab and teriparatide
Related Therapeutic Areas
Sponsors
Leads: Massachusetts General Hospital
Collaborators: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)